-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Vericiguat is an oral soluble guanylate cyclase (sGC) modulator, mainly used to treat patients with malignant chronic heart failure and reduced left ventricular ejection fraction (LVEF)
.
In the VICTORIA trial, patients treated with Vericiguat (7.
Recently, the heart blood vessels published a research article in the authoritative magazine on the field of Circulation, the researchers aimed to investigate Vericiguat, randomized hemoglobin, the association between anemia, as well as the benefits of Vericiguat whether related to baseline hemoglobin
.
Anemia is defined as male hemoglobin <13.
0g/dL and female <12.
Anemia is common after Vericiguat treatment, and lower hemoglobin is associated with a higher frequency of clinical events
Original source:
Justin A.
Ezekowitz,et al.
Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA) .
Circulation.
2021.
https:// 121.
Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA) in this message